Eligibility for PCSK9 treatment in 734 Hypercholesterolemic patients referred to a regional cholesterol treatment center with LDL cholesterol ⇿0 mg/dl despite maximal tolerated cholesterol lowering therapy
详细信息 查看全文
- 作者：Charles J. Glueck ; Parth Shah ; Naila Goldenberg…
- 关键词：PCSK9 inhibitors ; LDL cholesterol (LDLC) ; Heterozygous familial hypercholesterolemia (HeFH) ; Atherosclerotic cardiovascular disease (CVD)
- 刊名：Lipids in Health and Disease
- 出版年：2016
- 出版时间：December 2016
- 年：2016
- 卷：15
- 期：1
- 全文大小：730 KB
- 刊物主题：Lipidology; Medical Biochemistry;
- 出版者：BioMed Central
- ISSN：1476-511X
文摘
Background LDL cholesterol (LDLC) lowering has been revolutionized by PCSK9 inhibitors, Alirocumab (Praluent) and Evolocumab (Repatha), approved as adjuncts to maximally tolerated cholesterol lowering therapy in heterozygous (HeFH) or homozygous (HoFH) familial hypercholesterolemia, and/or clinical atherosclerotic cardiovascular disease (CVD) where LDLC lowering is insufficient.